首页> 外文OA文献 >CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes
【2h】

CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes

机译:CD154是1型糖尿病患者自身攻击性CD8 + T细胞的负调节剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

TNF/CD80 mice, a CD8+ T cell-mediated model for type 1 diabetes, transgenically express tumor necrosis factor α (TNF-α) and the costimulatory molecule CD80 in their pancreatic islets. Here we show that these molecules bypass the need for CD40–CD154 costimulatory interactions in activation of CD8+ T cells, allowing us to determine the role of CD40–CD154 signals in regulation of autoaggressive CD8+ T cells after their in vivo priming. TNF/CD80 CD154-deficient mice rapidly develop diabetes, whereas CD154-sufficient mice do not. This finding correlates with the decreased numbers of CD4+CD25+ T regulatory (TR) cells in the islets and pancreatic lymph nodes, in comparison to disease-protected CD154-sufficient mice. Administration of a CD40 agonistic antibody induces a systemic and tissue-specific increase in TR cells. However, this increase fails to delay diabetes development in the absence of CD154. Adoptive transfer studies show that CD8+ T cells from TNF/CD80 CD154-deficient, but not CD154-sufficient, mice are resistant to regulation in vivo. This study provides evidence that CD40-transduced signals initiate TR cell increase in vivo and that CD154-transduced signals sensitize autoaggressive CD8+ T cells to suppression.
机译:TNF / CD80小鼠是CD8 + T细胞介导的1型糖尿病模型,在其胰岛中转基因表达肿瘤坏死因子α(TNF-α)和共刺激分子CD80。在这里,我们证明了这些分子在激活CD8 + T细胞时绕过了CD40–CD154共刺激相互作用的需要,从而使我们能够确定CD40–CD154信号在体内启动后对自身攻击性CD8 + T细胞的调节作用。 TNF / CD80缺乏CD154的小鼠会迅速患上糖尿病,而CD154缺乏的小鼠则不会。与具有疾病保护的CD154的小鼠相比,该发现与胰岛和胰腺淋巴结中CD4 + CD25 + T调节(TR)细胞数量的减少有关。施用CD40激动性抗体可诱导TR细胞的全身性和组织特异性增加。但是,在没有CD154的情况下,这种增加不能延迟糖尿病的发展。过继转移研究表明,来自TNF / CD80 CD154缺陷型但不是CD154缺陷型小鼠的CD8 + T细胞对体内调节具有抗性。这项研究提供了证据,证明CD40转换的信号在体内引发TR细胞增加,而CD154转换的信号使自激性CD8 + T细胞对抑制敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号